The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says two more patients have responded to its Scope study, which brings the number of responders to 11 out of 13 patients. As a result, the objective response rate has increased to 85%. Notes one patient has achieved a complete response following treatment. The study has transitioned into the second stage, and Scancell plans to recruit a further 27 patients, with the aim to achieve at least 18 further responses. The trial investigates Scancell’s SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Scancell reported in mid-September that SCIB1 combined with checkpoint inhibitors showed an 82% objective response rate. Chief Executive Officer Lindy Durrant says: ‘The Scope study continues to yield excellent results with two more responders and one of the previous patients now achieving a complete response.’ Durrant says Scancell now expects the iSCIB1+ cohort to start in the first quarter of 2024.‘
----------
EnSilica PLC - Abingdon, Oxfordshire-based semiconductor designer and supplier - Says performance in the first half of the financial year ending May 31, has been ’resilient‘, buoyed by continued business momentum and ’significant‘ contracts with ’key customers‘. Remains confident in near-to-medium term prospects. Expects to trade in line with market expectations for financial 2024. EnSilica says analyst consensus currently forecast revenue of £22.9 million and earnings before interest, tax, depreciation and amortisation of £2.5 million.
----------
Orosur Mining Inc - South America-focused minerals explorer and developer - Says Lithium West joint venture has obtained results from its mapping and sampling programme, noting that ’abundant‘ pegmatites are evident, with lithium superoxide results in excess of 2%. Says two additional licences have been confirmed, with its land position in the key lithium districts expanded to 533 square kilometres. CEO Brad George says: ’These outstanding results from our first field program in Nigeria are exciting but not surprising. We pegged these licences with a very clear understanding of the geological processes in play, and so we expected to find lithium. To then confirm this confidence and to find so many lithium bearing pegmatites, some extremely thick, is very positive and bodes well for work on the next 5 licences that is underway now.‘
----------
Zenith Energy Ltd - Africa and Italy-focused oil and gas company - Signs memorandum of understanding with Nile Services & Logistics Co Ltd to jointly pursue business opportunities involving the construction of fuel products storage tanks, pipelines, and crude oil storage tanks in South Sudan. Zenith will provide technical, financial and managerial expertise in the construction of the tanks, while Nile Services will facilitate business opportunities. Zenith CEO Andrea Cattaneo says: ’We are very pleased to have now signed an MoU with Nile SLC, a subsidiary of the national oil company of South Sudan, and we look forward with enthusiasm to jointly exploring opportunities in the midstream domain and beyond, specifically with regards to petroleum product trading activities.‘ Also confirms that it is currently in the advanced phase of negotiating the potential acquisition of oil exploration and development licences in South Sudan.
----------
OptiBiotix Health PLC - York, England-based life sciences company - Inks deal with Ravenswood Ingredients Pty Ltd for the distribution of SlimBiome in Australia and New Zealand. ’Ravenswood brings access to the food and beverage markets and will complement existing partner capabilities which are largely focused on the meal replacement market to broaden OptiBiotix’s impact in Australia and New Zealand. This is part of a strategy of building partnerships to support expansion of OptiBiotix’s geographical footprint with companies who bring national and international capability for highly differentiated value-added ingredients in high growth markets around the world,‘ it says. CEO Stephen O’Hara comments: ’We are pleased to announce this agreement with Ravenswood who bring specialised food ingredient expertise as part of the Brenntag group, a global market leader in chemicals and ingredients distribution. This agreement is another example of OptiBiotix working with large partners and extends access to the food and beverage markets within Australia and New Zealand with a company which is part of a group which is a global leader in the ingredients market.‘
----------
Copyright 2023 Alliance News Ltd. All Rights Reserved.
